New hope for Hard-to-Treat esophagus condition
Disease control
NO_LONGER_AVAILABLE
This program provided expanded access to the experimental medication APT-1011 for people with eosinophilic esophagitis (EoE) who couldn't participate in regular clinical trials or had exhausted other treatment options. Patients received a 120-day supply of the oral dissolving tab…
Sponsor: Ellodi Pharmaceuticals, LP • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC